An individualized risk mitigation approach for safety: Experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk Meeting Abstract
| Authors: | Diefenbach, C.; Assouline, S.; Bosch, F.; Cheah, C. Y.; Kim, W. S.; Matasar, M. J.; Panizo, C.; Yoon, D. H.; Bender, B.; Hernandez, G.; Li, C. C.; McCall, B.; O'Hear, C.; Wei, M. C.; Yin, S.; Yousefi, K.; Kwan, A.; Nastoupil, L. J. |
| Abstract Title: | An individualized risk mitigation approach for safety: Experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164604140 |
| DOI: | 10.1182/blood-2019-123757 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4728 -- Source: Wos |
